Recent Finacing
Recent Raise
AvenCell develops switchable CAR‑T cell therapies for blood cancers, engineering CAR‑T cells with controllable on/off mechanisms to modulate activity and target hematologic malignancies.
Focus Areas
Total Raised
Funding round
See the team members at AvenCell.
